Intake of Marine ω-3 PUFAs Tied to Colorectal Cancer Survival

This article originally appeared here.
Share this content:
Intake of Marine ω-3 PUFAs Tied to Colorectal Cancer Survival
Intake of Marine ω-3 PUFAs Tied to Colorectal Cancer Survival

FRIDAY, July 22, 2016 (HealthDay News) -- Colorectal cancer (CRC) patients who consume higher amounts of omega-3 polyunsaturated fatty acids (PUFAs), mainly from oily fish, may have better odds of survival, according to a study published online July 19 in Gut.

Andrew Chan, M.D., of Massachusetts General Hospital in Boston, and colleagues tracked data on 1,659 patients diagnosed with CRC. During an average follow-up of about 10 years, 561 of the patients died. CRC was the cause of death in 169 cases, while other major causes of death included cardiovascular disease (153 cases) and other types of cancer (113 cases).

The researchers found that patients who consumed at least 0.3 g of omega-3 PUFAs per day after their CRC diagnosis were 41 percent less likely to die of the disease than those who consumed less than 0.1 g per day. The reduced risk was associated with omega-3 PUFAs from both food and fish oil supplements, but few of the patients used supplements, the researchers noted. The link between marine omega-3 PUFAs and lower risk of death from CRC was particularly strong for patients who were taller, relatively thin, and did not take aspirin regularly.

The researchers found that increasing intake of omega-3 PUFAs by at least 0.15 g per day after a CRC diagnosis was associated with a 70 percent lower risk of dying from the disease, while a reduction in daily intake was associated with a 10 percent higher risk of death from the disease. The all-cause mortality risk was also 13 percent lower in those who increased their intake of omega-3 PUFAs, but 21 percent higher among those who decreased their intake.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

ASTRO: No Survival Benefit for Adding EBT to ...

Addition of external beam therapy doesn't improve five-year progression-free survival in prostate cancer

ASTRO: Fewer Side Effects With IMRT in Cervical, Endometrial CA

ASTRO: Fewer Side Effects With IMRT in Cervical, ...

Patients in conventional radiotherapy arm had more high-level adverse events than those in IMRT arm

Many Doctors Reluctant to Reveal Mental Health Issues

Many Doctors Reluctant to Reveal Mental Health Issues

Perceived stigma, fear of career repercussions hinder treatment, study suggests

is free, fast, and customized just for you!

Already a member?

Sign In Now »